Oct. 27 at 7:47 PM
$SLDB @pharmd2828 Are you referring to following Catalysts?? Specially SGT-003?
- Duchenne (SGT-003): 15 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial and dosing remains ongoing; On track to discuss regulatory pathways with U.S. FDA in Q4 2025 -
- FA (SGT-212): Phase 1b trial initiation expected in Q4 2025 -
- CPVT (SGT-501): Phase 1b trial initiation expected in Q4 2025 -
- Capsids (AAV-SLB101): Over 25 agreements or licenses with academic labs, institutions and corporations for the use of AAV-SLB101 have been executed -